Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563663 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL129846 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL29858755 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL2627039 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL193981 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL29764040 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL29484136 | 0.98 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL432891 | 0.98 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL29484132 | 0.98 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP | |
| Hydrochloric Acid SCHEMBL431787 | 0.98 | ITGB2 (0.44) | ITGB2ICAM1ITGALLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112209991-B | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-08-12 | — | — | CN | claimed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-7094909-B2 | Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group | AGOURON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| US-6919347-B2 | Bradykinin B1 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1409466-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1196411-B1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002100844-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1196411-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005783-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | ITGB2 3990/4885ICAM1 4866/4885ITGAL 3617/4885 |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | ITGB2 2054/4885ICAM1 4770/4885ITGAL 3208/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ITGB2 3532/4885ICAM1 4841/4885ITGAL 3976/4885 |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | ITGB2 2784/4885ICAM1 1603/4885ITGAL 2556/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ITGB2 3086/4885ICAM1 4773/4885ITGAL 3501/4885 |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | FURIN, PREP, PRSS1 | ITGB2 4387/4885ICAM1 1618/4885ITGAL 3682/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | ITGB2 2921/4885ICAM1 205/4885ITGAL 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.